ABBV: AbbVie Inc. $205.07
AbbVie is trading at an extreme oversold level with an RSI of 12.3, presenting a potential technical rebound opportunity, but the consensus upside is just shy of our BUY threshold.
52-wk High $244.81
📌 Investment Snapshot
- 💰 Price & Valuation: Trading at $205.07 with a P/E of 86.2x, a significant premium to the S&P 500 average.
- 📈 Latest Quarter: Q4 FY25 revenue hit $16.6B, up +10.0% YoY, with EPS of $1.02.
- 🔑 #1 Catalyst: The stock is deeply oversold with an RSI of 12.3, suggesting a strong technical rebound potential from current levels.
- 🎯 Consensus: BUY rating with a mean target of $249, implying +21.4% upside.
| 📍 Entry Zone | $205 or below | 🛑 Stop-Loss | $195 |
| 📋 Adjust If | RSI fails to rebound above 30 or Q1 FY26 earnings disappoint. | ||
The Investment Case — Why Now?
AbbVie finds itself at a critical juncture, with its stock price recently dipping to $205.07, pushing its 14-day RSI to an extremely oversold 12.3. This technical setup, combined with the stock trading below its 50-day and 200-day simple moving averages, signals a potential rebound opportunity for investors seeking value in a beaten-down healthcare giant. The company’s Q4 FY25 revenue growth of +10.0% YoY to $16.6B demonstrates underlying business strength despite market pressures.
However, the primary risk that could break this thesis remains the ongoing impact of biosimilar competition for Humira, its blockbuster drug, and the need for new pipeline assets like Skyrizi and Rinvoq to fully offset revenue declines. While these newer drugs are performing well, any slowdown in their growth or unexpected pipeline setbacks could further pressure the stock, especially given its elevated P/E ratio of 86.2x compared to the sector average.
Company Overview
| Label | Value |
|---|---|
| Company | AbbVie Inc. |
| Ticker / Exchange | ABBV / NYSE |
| Sector / Industry | Healthcare / Drug Manufacturers – General |
| CEO | Richard A. Gonzalez |
| Founded / HQ | 2013 / North Chicago, IL |
Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| ABBV | (This stock) | 86.2x |
| S&P 500 Avg | S&P 500 Avg | 21.0x |
| UNH | UnitedHealth Group Incorporate | 20.8x |
| JNJ | Johnson & Johnson | 21.3x |
| LLY | Eli Lilly and Company | 39.5x |
| PFE | Pfizer, Inc. | 19.8x |
Price Action & Technicals
$205.07
-8.8%
-7.2%
-16.23%
AbbVie’s current price of $205.07 is trading significantly below its 50-day SMA of $222.91 and 200-day SMA of $213.04, indicating strong bearish momentum. The 14-day RSI at 12.3 suggests the stock is deeply oversold, while the MACD remains in neutral territory with a negative reading.
Furthermore, the price is below the lower Bollinger Band ($206.65), positioning it at -4.4% relative to the band, which often precedes a rebound. Volume has also seen a significant surge, with a ratio of 3.69x against its 20-day average, indicating heightened investor interest at these depressed levels.
Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 FY25 | $16.6B | $1.02 | +10.0% |
| Q3 FY25 | $15.8B | $0.10 | +9.1% |
| Q2 FY25 | $15.4B | $0.52 | +6.6% |
| Q1 FY25 | $13.3B | $0.72 | +8.4% |
AbbVie has consistently delivered strong revenue growth, with the latest Q4 FY25 reporting $16.6B, marking a +10.0% YoY increase. This sustained performance indicates resilience despite the challenges of patent expirations.
The company maintains a robust cash flow, enabling it to fund its dividend yield of 3.37% and strategic share buybacks, reinforcing shareholder returns amidst its ongoing portfolio transformation.
Growth Drivers — What Moves the Stock
- New Product Launches & Pipeline Expansion: Continued strong uptake of immunology drugs Skyrizi and Rinvoq, along with successful development and commercialization of new assets in oncology and neuroscience, are critical for long-term revenue diversification. 🟢
- International Market Growth: Expansion into key emerging markets and increased penetration in established international territories for its diversified portfolio can provide significant revenue uplift beyond the U.S. market. 🟢
- Strategic Acquisitions & Partnerships: Opportunistic M&A or licensing deals that bolster its pipeline or add complementary therapeutic areas could accelerate growth and reduce reliance on existing blockbusters. 🟡
Smart Money & Institutional Positioning
Institutional Holdings (Top 5)
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 180,779K |
| Blackrock Inc. | 151,174K |
| State Street Corporation | 80,940K |
| JPMORGAN CHASE & CO | 52,393K |
| Geode Capital Management | 44,629K |
Holdings reflect most recent 13F (45-day lag). QoQ change not available.
Short Interest
| Metric | Value |
|---|---|
| Short % of Float | 1.23% |
| Days to Cover | 3.1 |
Short interest in ABBV is very low, indicating minimal bearish positioning and negligible potential for a short squeeze.
Key Risk Factors — Risk Matrix
Patent Expiry & Biosimilar Competition
Continued erosion of Humira sales due to biosimilar competition could impact revenue and profitability more severely than anticipated.
~>$15B impact
R&D Pipeline Success & Execution
Failure of key pipeline assets to meet clinical endpoints or gain regulatory approval could limit future growth drivers.
~>$15B impact
Regulatory & Pricing Pressures
Increased government scrutiny on drug pricing or new regulations could impact profitability and market access for key products.
~$8B impact
Macroeconomic Headwinds
Broader economic downturns or shifts in healthcare spending patterns could indirectly affect prescription volumes and patient access.
~$3B impact
Guidance & Wall Street View
Management has indicated continued focus on the strong performance of its non-Humira portfolio, particularly Skyrizi and Rinvoq, to drive future growth and offset the impact of biosimilar competition. While specific forward guidance figures for Q1 FY26 are not provided in the current data, the emphasis remains on pipeline execution and market expansion.
Recent Analyst Actions
| Firm | Rating | Price Target | Date | Action |
|---|---|---|---|---|
| RBC Capital | Outperform | $260.00 | 2026-02-25 | Initiate |
| Barclays | Overweight | $275.00 | 2026-02-20 | Initiate |
| Piper Sandler | Overweight | $299.00 | 2026-02-18 | Maintain |
| UBS | Neutral | $230.00 | 2026-02-05 | Maintain |
| Evercore ISI Group | Outperform | $228.00 | 2026-02-05 | Maintain |
Analyst Consensus
| High Target | Mean Target | Low Target | Total Analysts | Consensus Rating |
|---|---|---|---|---|
| $299 | $249 | $184 | 29 | BUY |
The analyst consensus for AbbVie is a BUY, with a mean target price of $249, representing a potential +21.4% upside from the current price. The target range is wide, from a high of $299 to a low of $184, indicating varied views on the company’s ability to navigate post-Humira growth.
Bull vs Bear — Probability-Weighted Scenarios
Bull Case
- Stronger-than-expected growth from Skyrizi and Rinvoq, coupled with successful new drug launches, could rapidly offset Humira’s decline and drive market share gains.
- Successful pipeline execution in oncology and neuroscience, leading to new blockbuster drugs that significantly diversify revenue streams and improve margins.
Implied Target: $299
Base Case
AbbVie continues its transition post-Humira, with steady but not explosive growth from its newer immunology drugs. The company manages biosimilar competition effectively, and its pipeline delivers incremental, rather than transformative, successes. This scenario aligns with current analyst consensus, suggesting a fair value around the mean target.
Implied Fair Value: $249
Bear Case
- More aggressive biosimilar erosion or unexpected competition for Skyrizi/Rinvoq, leading to slower growth and missed revenue targets.
- Pipeline setbacks or regulatory hurdles for late-stage assets, resulting in a lack of new revenue drivers to compensate for mature product declines.
Implied Target: $184
Disclaimer & Hashtags
This Veqtio analysis is for informational and educational purposes only and does not constitute investment advice. All investment decisions should be made based on your own thorough research and consultation with a financial professional. Veqtio does not endorse any specific investment or financial strategy.
All active positions and their real-time performance are tracked on our Investment Log.
#ABBV #AbbVie #USStocks #StockAnalysis #Veqtio #Healthcare #DrugManufacturers #Pharma